1. 1) U.S. Food and Drug Administration. “Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications.”: ‹https://www.fda.gov/news-events/press-announcements/statement-agencys-ongoing-efforts-resolve-safety-issue-arb-medications›, cited 31 March, 2020.
2. 2) Masada S., Tsuji G., Arai R., Uchiyama N., Demizu Y., Tsutsumi T., Abe Y., Akiyama H., Hakamatsuka T., Izutsu K. I., Goda Y., Okuda H., Sci. Rep., 14, 11852 (2019).
3. 3) Parr M. K., Joseph J. F., J. Pharm. Biomed. Anal., 164, 536–549 (2019).
4. 4) Sörgel F., Kinzig M., Abdel-Tawab M., Bidmon C., Schreiber A., Ermel S., Wohlfart J., Besa A., Scherf-Clavel O., Holzgrabe U., J. Pharm. Biomed. Anal., 172, 395–405 (2019).
5. 5) Tsutsumi T., Akiyama H., Demizu Y., Uchiyama N., Masada S., Tsuji G., Arai R., Abe Y., Hakamatsuka T., Izutsu K. I., Goda Y., Okuda H., Biol. Pharm. Bull., 42, 547–551 (2019).